Analysts’ Recent Ratings Updates for Edwards Lifesciences (EW)

Edwards Lifesciences (NYSE: EW) recently received a number of ratings updates from brokerages and research firms:

• 1/12/2026 – Edwards Lifesciences had its “neutral” rating reaffirmed by analysts at UBS Group AG. They now have a $95.00 price target on the stock, up previously from $92.00.
• 1/12/2026 – Edwards Lifesciences was given a new $90.00 price target on by analysts at Robert W. Baird.
• 1/12/2026 – Edwards Lifesciences had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a $104.00 price target on the stock, up previously from $103.00.
• 1/9/2026 – Edwards Lifesciences was upgraded by analysts at Cowen Inc from a “hold” rating to a “buy” rating.
• 1/9/2026 – Edwards Lifesciences had its “buy” rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They now have a $108.00 price target on the stock.
• 1/9/2026 – Edwards Lifesciences was upgraded by analysts at TD Cowen from a “hold” rating to a “buy” rating. They now have a $97.00 price target on the stock, up previously from $90.00.
• 1/7/2026 – Edwards Lifesciences had its price target raised by analysts at Stifel Nicolaus from $100.00 to $105.00. They now have a “buy” rating on the stock.
• 1/5/2026 – Edwards Lifesciences had its “outperform” rating reaffirmed by analysts at Evercore ISI. They now have a $94.00 price target on the stock.
• 12/18/2025 – Edwards Lifesciences was given a new $100.00 price target on by analysts at Wells Fargo & Company.
• 12/18/2025 – Edwards Lifesciences was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating. They now have a $100.00 price target on the stock, up previously from $90.00.
• 12/17/2025 – Edwards Lifesciences was given a new $87.00 price target on by analysts at Canaccord Genuity Group Inc.. They now have a “hold” rating on the stock.
• 12/16/2025 – Edwards Lifesciences was given a new $87.00 price target on by analysts at Robert W. Baird. They now have a “neutral” rating on the stock.
• 12/11/2025 – Edwards Lifesciences had its “buy” rating reaffirmed by analysts at Citigroup Inc.. They now have a $101.00 price target on the stock, up previously from $96.00.
• 12/8/2025 – Edwards Lifesciences had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a $103.00 price target on the stock, up previously from $99.00.
• 12/5/2025 – Edwards Lifesciences was given a new $92.00 price target on by analysts at UBS Group AG.
• 12/5/2025 – Edwards Lifesciences was given a new $89.00 price target on by analysts at Canaccord Genuity Group Inc..
• 12/5/2025 – Edwards Lifesciences had its “overweight” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $96.00 price target on the stock, up previously from $95.00.
• 12/5/2025 – Edwards Lifesciences was given a new $100.00 price target on by analysts at Stifel Nicolaus. They now have a “buy” rating on the stock.
• 12/5/2025 – Edwards Lifesciences was given a new $92.00 price target on by analysts at Truist Financial Corporation. They now have a “hold” rating on the stock.
• 12/5/2025 – Edwards Lifesciences had its “hold” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $89.00 price target on the stock, up previously from $84.00.
• 12/5/2025 – Edwards Lifesciences had its price target raised by analysts at Royal Bank Of Canada from $95.00 to $100.00. They now have an “outperform” rating on the stock.
• 12/5/2025 – Edwards Lifesciences had its price target raised by analysts at Robert W. Baird from $83.00 to $88.00. They now have a “neutral” rating on the stock.
• 12/4/2025 – Edwards Lifesciences had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $103.00 price target on the stock, up previously from $100.00.
• 12/3/2025 – Edwards Lifesciences had its “neutral” rating reaffirmed by analysts at UBS Group AG. They now have a $92.00 price target on the stock, up previously from $90.00.
• 11/25/2025 – Edwards Lifesciences had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $100.00 price target on the stock.

Insider Activity at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the sale, the chief financial officer directly owned 39,898 shares in the company, valued at $3,314,725.84. The trade was a 24.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the sale, the vice president owned 22,002 shares in the company, valued at $1,816,265.10. This represents a 4.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 57,824 shares of company stock valued at $4,863,323. 0.34% of the stock is owned by corporate insiders.

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.